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SUMMARY
While mouse models have been relatively poor at recapit-
ulating true adenocarcinoma in the gastric corpus, a number
of models have been successful in modeling pre-neoplastic
metaplasias. These models demonstrate key insights into the
origins of metaplasia and their modulation by intrinsic
mucosal and immune cell-derived factors.
Intestinal-type gastric adenocarcinoma evolves in a ﬁeld of
pre-existing metaplasia. Over the past 20 years, a number
of murine models have been developed to address aspects
of the physiology and pathophysiology of metaplasia in-
duction. Although none of these models has achieved true
recapitulation of the induction of adenocarcinoma, they
have led to important insights into the factors that inﬂu-
ence the induction and progression of metaplasia. Here, we
review the pathologic deﬁnitions relevant to alterations in
gastric corpus lineages and classiﬁcation of metaplasia by
speciﬁc lineage markers. In addition, we review present
murine models of the induction and progression of spas-
molytic polypeptide (TFF2)–expressing metaplasia, the
predominant metaplastic lineage observed in murine
models. These models provide a basis for the development
of a broader understanding of the physiological and path-
ophysiological roles of metaplasia in the stomach. (Cell Mol
Gastroenterol Hepatol 2017;3:11–26; http://dx.doi.org/
10.1016/j.jcmgh.2016.11.001)
Keywords: SPEM; Intestinal Metaplasia; Gastric Cancer; TFF2;
Chief Cell; Hyperplasia.
Gastric adenocarcinoma is a leading cause of world-wide cancer-related deaths. Poor clinical outcomes
result from the lack of early clinical indicators and late
presentation. Insights into the progression of preneoplastic
processes that promote gastric cancer therefore are needed
to facilitate early intervention in gastric carcinogenesis.
The sequence of metaplasia to neoplasia is at the root of the
most common type of gastric cancer worldwide, intestinal-
type adenocarcinoma, which occurs in the setting of
chronic infection with the bacterium Helicobacter pylori.
Murine models currently used are helpful in understanding
the molecular mechanisms that drive the development of
metaplasia in the stomach and its progression toward
neoplasia. Unfortunately, no mouse models have reproduced
the human later-stage progression to a true intestinal-type
cancer with tumor masses that lead to local or distal
metastasis. In short, the greatest utility of mouse models lies
in the analysis of mechanisms that are responsible for the
induction and progression of precancerous lesions, in
particular, metaplasia. The following discussion examines
models of metaplasia and gastric neoplasia in the corpus of
mice and the insights they can provide into the origin and
progression of human disease. To aid in interpretation of the
various speciﬁc models, we ﬁrst offer a primer on the terms
used for the relevant mouse lesions in the stomach.
Deﬁnition of Hyperplastic, Metaplastic,
and Preneoplastic Lineages in Mouse
Stomach Models
The nomenclature used to describe the gastric pathology in
the mouse stomach has never been standardized. Inconsistent
terminology hinders progress toward developing and inter-
preting models that can help elucidate the molecular and
cellular progression of metaplastic pathology. Establishing
terminology that is speciﬁc for particular pathologic features is
necessary to accurately classify cellular changes at key stages.
Later, we attempt to deﬁne the most commonly observed le-
sions in a way that we hope will guide interpretation of future
experiments. First, however, we must deﬁne some key pa-
thology terms we use to describe the lesions: hyperplasia,
metaplasia, and dysplasia. Hyperplasia refers to a pathologic
lesion characterized by expansion of a normal cell lineage that
resides in the tissue where it normally is found. Metaplasia
refers to the presence of an otherwise normal cell lineage (or
lineages) in a tissue where such a lineage is not normally
found. Dysplasia is the presence of cellswith abnormal cellular
features and implies that the cells,which could resemble either
normal or metaplastic lineages, have acquired mutations or
Abbreviations used in this paper: ATPase, adenosine triphosphatase;
BMP, bone morphogenic protein; EGF, epidermal growth factor;
EGFR, epidermal growth factor receptor; Hip1r, Huntington interacting
protein 1 related; IFN, interferon; MUC, mucin; SDF1, stromal-derived
factor 1; SPEM, spasmolytic polypeptide–expressing metaplasia; TFF,
trefoil factor; Tg, transgene; TGF, transforming growth factor; Th, T-
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epigenetic alterations that provide increased risk for malig-
nant (eg, invasive) progression.
Oxyntic Atrophy
Atrophy, to a pathologist, means loss of cells. Parietal
cells, whose primary job is to secrete acid, also are known as
oxyntic cells. Thus, oxyntic atrophy is the pathologic process
characterized by loss of parietal cells. In human beings and
mouse models, loss of parietal cells usually correlates with
the onset of metaplastic lesions, such that oxyntic atrophy
has been termed the sine qua non for metaplasia.1,2 In hu-
man beings and mice, chronic Helicobacter infection can
lead to loss of parietal cells in the corpus of the stomach.3–6
Oxyntic atrophy is diagnosed easily on H&E staining
because the absence of highly eosinophilic parietal cells is
obvious. During oxyntic atrophy, mature chief cells (diges-
tive enzyme–secreting or zymogenic), which are mixed H&E
positive, also are absent. Work in mouse models and human
beings suggests that the loss of mature chief cells may not
simply be because they all die similar to parietal cells, but
rather that chief cells, in response to loss of parietal cells,
change their differentiation state. Speciﬁcally, they repro-
gram into metaplastic mucous cells.7–11 Such a reprogram-
ming of cell fate also is known as transdifferentiation. For a
more deﬁnitive analysis beyond H&E, cell-type and lineage-
speciﬁc markers can be used with immunoﬂuorescent or
immunohistochemical techniques: for example, antibodies
against the proton pump, Hþ/Kþ–adenosine triphosphatase
(ATPase) (a or b subunit) will label only mature parietal
cells, whereas antibodies against the basic Helix-Loop-Helix
transcription factor, MIST1 (A15), will label only chief
cells.2,7,12
Foveolar Hyperplasia
Foveolar cells are the simple columnarmucous cells lining
the surface of the stomach and extending downward toward
the gastric gland (Figure 1). They face the harshest condi-
tions, being closest to the lumen of the stomach, and turn over
the fastest.13,14 Gastric units are shaped roughly like a funnel,
with the glandular portion (the part with the parietal and
chief cells) below the neck of the funnel, and the foveolar cells
in the widemouth.15 Thus, the foveolar region also resembles
the opening to a pit. Hence, foveolar cells also are known as
pit cells in the literature. Hyperplasia, as mentioned, is an
expansion of normal cells. Hence, foveolar hyperplasia rep-
resents an expansion of these surface or pit mucous cells.
Foveolar hyperplasia (Figure 1) usually is associated with an
increase in proliferation in the normal progenitor cells in the
isthmus of the gastric unit.10 A common cause of foveolar
hyperplasia in mice and human beings is an increase of
gastrin.16 Increased signaling through the epidermal growth
factor (EGF) receptor (eg, by increased abundance of its
ligand transforming growth factor a) also causes foveolar
hyperplasia; human Ménétrier disease is caused by such
overactive signaling.17,18 Interestingly, oxyntic atrophy and
foveolar hyperplasia often are linked. Long-term loss
of parietal cells causes decreased stomach acid (hypochlo-
rhydria), which causes gastrin-secreting cells in the antrumof
the stomach (G cells) to secrete gastrin in an attempt to
stimulate parietal cell function. The increased gastrin has
several effects, including inducing foveolar hyperplasia.10
Gastrin-secreting tumors of the gastrointestinal tract (as oc-
curs in Zollinger–Ellison syndrome), also can result in
foveolar hyperplasia.19 Thus, in general, foveolar hyperplasia
correlates with hypochlorhydria and hypergastrinemia.
Mucous Neck Cell Hyperplasia/
Mucinous Metaplasia
Mucous neck cell hyperplasia connotes expansion of
normal mucous neck cells (Figure 1). A related term often
used by pathologists, especially veterinary pathologists, is
mucous metaplasia, which often may be the same lesion as
mucous neck cell hyperplasia. A reason for the possible
confusion is that mucous metaplasia typically is diagnosed
by conventional histochemical staining (H&E, periodic
acid–Schiff, and Alcian blue). It describes a lesion charac-
terized by abnormally increased numbers of mucous-
expressing neck cells in the glands of the stomach (ie, not
in the foveolar/pit region). In our experience, mucinous
metaplasias usually are caused by expansion speciﬁcally of
normal mucous neck cells. Thus, mucous metaplasia is often
a misnomer because no new (metaplastic) cell lineages are
found in the stomach. Mucous neck cells may have a
metaplastic look when they expand markedly because in the
normal stomach they usually are difﬁcult to see, given that
their cytoplasms do not stain with H&E, and those non-
staining cytoplasms are localized predominantly in the
lumen of the gland because parietal cells occupy the vast
majority of the basement membrane.20 When mucous neck
cells expand signiﬁcantly, they do so at the expense of pa-
rietal cells, giving a morphology that appears as if a new
population of cells has appeared. On immunohistochemical
or immunoﬂuorescent staining, however, the cells in these
lesions label exclusively with mucous neck cell lineage
markers (including Griffonia simplicifolia lectin (GS-II),
Trefoil factor 2 (TFF2), mucin 6 (MUC6), and gastrokine 3
(GKN3)).21,22 Thus, this lesion is best described as mucous
neck cell hyperplasia.
Mucous neck cell hyperplasia has been reported in a
number of settingswith alterations of ion channels (eg, loss of
KVLQT1) or endocrine cell inﬂuences.22 In our experience,
mucous neck cell hyperplasia also arises spontaneously in
otherwise healthy mice. The lesion usually is focal and char-
acterized by a neutrophil-predominate inﬂammatory inﬁl-
trate. The expansion of mucous neck cells usually is not
associated with markedly increased proliferation within the
mucous neck cell population, but rather appears to reﬂect
either an increased production of mucous neck cells from
multipotent progenitors or a slowing of differentiation of
mucous neck cells into chief cells.7,23 It is important to note
that combinations of mucous neck cell hyperplasia can exist
in association with other truly metaplastic lesions. For
example, spasmolytic polypeptide (TFF2)-expressing meta-
plasia (SPEM), which will be discussed later, often is char-
acterized by abundant mucous-containing cells (Figure 1).
SPEM may look like mucous neck cell hyperplasia on
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Figure 1. Hyperplastic lesions
in the gastric corpus. (A)
Normal gastric mucosa stained
with Ulex Europaeus Agglutinin
I (UEA-I) lectin for surface cells
(inverse greyscale), GSII lectin
for mucous neck cells (green),
antibodies against H/K-ATPase
for parietal cells (red), and
antibodiesagainstGIF (blue). (B)
Mucosal section showing
foveolar hyperplasia after
3 days dosing of DMP-777
stained with UEA-I (blue),
H/K-ATPase (red), and GSII
(green). (C) Mucosa with mu-
cous neck cell hyperplasia
stained with antibodies against
vascular endothelial growth
factor (VEGF)-B for parietal cells
(red) and GSII lectin (GSII).
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histochemical stain, and it can combinewithmucous neck cell
hyperplasia.7
Spasmolytic Polypeptide (TFF2)-Expressing
Metaplasia/Pseudopyloric Metaplasia/
Antralization
Loss of parietal cells in mice or human beings correlates
with the induction of metaplasia in the corpus
glands.2,7,10,12,24–26 In particular, as mentioned previously,
this oxyntic atrophy is characterized by loss of mature chief
cells. As mentioned earlier, mouse models and examination
of human tissue suggest that many of these chief cells do not
die, but actually transdifferentiate or reprogram into a
metaplastic mucous-secreting lineage: SPEM. SPEM shares
many features with the cells that populate the gland in
embryonic and juvenile stomach.7,11,12,27 Namely, SPEM is
characterized by expression of lower levels of chief cell
proteins (such as the digestive enzyme pepsinogen C and, in
mice, gastric intrinsic factor), with markers of mucous neck
cells (TFF2, GKN3, and MUC6) (Figure 2). The pattern of
corpus units that have no parietal cells and abundant basal
cells co-expressing chief and neck cell markers is similar to
the organization, at least at the superﬁcial level, of units in
the more distal stomach (the antrum or pylorus) (Figure 1).
Thus, this lesion also has been termed “pseudopyloric
metaplasia,” representing a process of “antralization.”28
SPEM also may represent a reparative lineage equivalent
to the ulcer-associated lineages identiﬁed in association
with healing mucosa in inﬂammatory bowel disease.29
Indeed, recent studies have noted that SPEM develops at
the edges of healing gastric ulcers and contributes to ulcer
healing.30,31
As mentioned, it is thought that SPEM cells arise in part
via reprogramming/transdifferentiation of chief cells. The
key evidence is that lineage mapping studies in mice using
the Mist1 reporter of chief cell differentiation have shown
that SPEM cells emerging during loss of parietal cells were
once MIST1-positive (ie, they were chief cells).7 The chief
cells that reprogram after loss of parietal cells down-
regulate expression of chief cell differentiation markers
(eg, the endogenous Mist1 gene) and begin to express high
levels of proteins that were expressed in mucous neck cell
lineages, including TFF2 and MUC6.25,26,32 Thus, the
metaplastic cells can be identiﬁed in the base of gastric
glands (the normal niche for chief cells) by strong immu-
nolabeling for TFF2, which is the origin for the moniker
SPEM.33–35 This lineage often can be identiﬁed by pink
staining in diastase-resistant periodic acid–Schiff staining,
compared with the purple staining in surface mucous
cells.24 Most importantly, SPEM glands usually show,
especially at their bases, hybrid cells, which express both
chief cell markers (eg, intrinsic factor in mice) and mucous
cell markers (eg, TFF2, MUC6, or GS-II lectin).2,25,26,36
SPEM is a true metaplasia because SPEM-type cells are
not normal corpus lineages, but resemble deep antral gland
cells.27
Markers to positively determine SPEM. SPEM cannot
be determined deﬁnitively in the antrum, where deep mu-
cous gland cells show many of the same characteristics. It is
a lesion speciﬁcally of glands from the corpus/body (also
known as fundic-type glands) that develop metaplasia.
SPEM likely occurs with similar characteristics in all mam-
mals, but has been documented deﬁnitively in mice, rats,
gerbils, and human beings.10,33–35,37 The organization of
SPEM glands, as mentioned, superﬁcially resembles the
antrum, with TFF2-positive cells also labeling with a lower
abundance of chief cell markers (gastricintrinsic factor in
mice, or pepsinogen C), and the center of proliferation
moves from near the gastric lumen (at the isthmus, where
the funnel of pit/foveolar cells meet the deeper glandular
cells) in the normal oxyntic gland, toward the base in SPEM
glands. SPEM cells often show proliferation with TFF2/GIF
dual-positive cells also labeling with Ki-6737 or nucleotide
analogs such as bromodeoxyuridine, especially in the pres-
ence of inﬂammation.20 Investigations have identiﬁed some
biomarkers of SPEM that do not appear in normal corpus
lineages including HE-4 (WFDC2)25 and CD44 variant 9.38 It
also is clear in human patients and in animal models that
morphologically apparent SPEM lineages often can show
varying levels of intestinalizing transcripts including TFF3,
MAL2, CFTR, and MUC4.36,39 This intestinalized SPEM is
morphologically identical to other SPEM lineages and can be
recognized only by immunostaining with speciﬁc intestinal
markers.36
Intestinal Metaplasia
Although both SPEM and intestinal metaplasia are
present in the stomachs of human beings with atrophic
gastritis secondary to H pylori infection,2,12 few instances
of documented intestinal metaplasia exist in mouse models.
In human stomach, Alcian blue staining of intestinal-type
goblet cells often is used to deﬁne intestinal metaplasia.
However, murine deep antral mucous cells and SPEM often
both are strongly Alcian blue positive.24 Thus, more spe-
ciﬁc markers are required in mice. MUC2 and TFF3 labeling
of cells with intestinal goblet cell–like morphology pro-
vides the most speciﬁc indication of intestinal metaplasia
(Figure 2C).12 Notably, expression of TFF3 and MUC2 has
been reported in lineages with immunocytochemical evi-
dence of SPEM, so there may be intermediates of intesti-
nalized SPEM that reﬂect evolution of metaplastic
phenotypes.36,40 Expression of nuclear CDX1 and CDX2 has
Figure 2. (See previous page).Metaplastic lesions in the mouse gastric corpus. (A) Corpus section with SPEM stained with
GSII lectin (green), Ulex Europaeus Agglutinin I (UEA-I)-I lectin (blue), and Ki-67 (Red). (B) Section with proliferative SPEM with
intestinalizing characteristics stained with GSII lectin (green), UEA-I lectin (blue), and Ki-67 (Red). (C) Section with intestinal
metaplasia stained with Muc2 (green), GSII lectin (red), and 40,6-diamidino-2-phenylindole (DAPI) (blue). (D) Section with
penetrating submucosal gland stained for TFF2.
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been noted in human intestinal metaplasia,41 but has been
less apparent in mouse models. MUC2-positive goblet cells
have been identiﬁed in older amphiregulin knockout
mice.42 More recently, CDX1-positive cells and MUC2-
positive goblet cells have been observed in Mist1-Kras
(G12D) mice, but CDX2 expression was not observed.43
The expression of CDX1 rather than CDX2 may reﬂect the
more prominent expression of CDX1 in the duodenum,
consistent with the concept that intestinal metaplasia in
the stomach may represent more speciﬁcally a “duodenal
metaplasia.”44 Indeed, previous studies have suggested that
intestinal metaplasia in the human corpus may reﬂect a
duodenal lineage paradigm based on PDX1 expression.44 It
is notable that forced expression of the intestinal master
regulatory transcription factor Cdx2 in the stomach caused
complete intestinalization of the stomach mucosa.45,46
However, it is difﬁcult to interpret these results within
the context of adult-onset metaplasia because the gastric
epithelium in these mice was speciﬁed during development
with forced expression of an intestine-promoting tran-
scription factor in cells that otherwise would have become
stomach. Thus, the epithelium in this case simply may be
(developmentally) intestine, rather than metaplastic
stomach. Only speciﬁc marker staining can differentiate
between SPEM with intestinalizing characteristics and
frank intestinal metaplasia with the presence of goblet cells
and villin-expressing absorptive cells.43
Invasive Submucosal Glands
The presence of glands penetrating into the submucosa
(sometimes referred to as gastritis cystica profunda) usually
is considered a dysplastic lesion in human beings. For
example, the presence of gastritis cystica profunda in human
beings has been noted decades after gastrojejunostomy for
ulcer disease and is considered a preneoplastic lesion.47
Intermediate levels of penetrating or invasive glands also
can be observed. Although invasive submucosal glands have
been reported in H pylori–infected Mongolian gerbils, some
investigations have indicated that invasive glands are
reversible after bacterial eradication.48 Recent detailed
studies in gerbils have noted that invasive submucosal
glands usually are connected to SPEM glands within the
mucosa.49 Numerous mouse models have assumed that
invasive glands are synonymous with dysplasia or even
invasive neoplasia (malignancy).3,4,50 However, we are un-
aware of any models in which investigators have shown
truly neoplastic qualities in these lesions. As noted in mouse
models of colon cancer,51 in our experience, the mouse
stomach has a propensity for extension of metaplastic le-
sions. In some occasions, tremendous proliferation in the
epithelium can result in cross-sectional cuts of the tissue that
appear invasive but are not. In other cases, the epithelial
cells in the mucosa actually may breach the relatively thin
muscularis mucosa of the mouse stomach. Although these
glands thus technically might appear to be invasive, the ex-
amples we have observed in the literature and in our own
studies do not show any additional features of neoplasia. In
other words, such invasive glands remain symmetrical and
are indistinguishable from surrounding metaplastic glands
that are not apparently in the submucosa. Furthermore, the
glands in question typically do not show other signs of
dysplasia/neoplasia, such as: loss of nuclear polarity, cells
piling up with nuclear crowding, irregular gland forms with
an invasive-seeming leading edge, nuclear atypia, or sur-
rounding stromal hyperplasia (desmoplasia). In addition,
these invasive glands usually are populated by TFF2-positive
lineages (Figure 2D) and do not show proliferative rates any
greater than associated intramucosal SPEM. Furthermore,
we are unaware of models showing metastatic behavior
typical of invasive adenocarcinomas of the stomach in hu-
man beings. Thus, there is no evidence that such glands
actually invade the way human tumors do. Therefore, the
neoplastic implications of seemingly invasive submucosal
glands, which might be assumed in human beings to be
premalignant lesions, are unclear in mouse models.
Dysplasia
Dysplastic phenotypes are deﬁned by cellular and
glandular morphologies on H&E staining. No speciﬁc
markers of dysplasia exist. The interpretation of dysplasia
therefore is fraught with controversy even among human
pathologists diagnosing lesions in patients. The importance
of a dysplasia diagnosis is essentially that it is prognostic
for increased progression to cancer. Given that no actual
metastatic or truly invasive adenocarcinoma models in the
mouse stomach seem to exist, it is difﬁcult to deﬁne the
term dysplasia in a standard way in mouse models. If used,
it must be strictly deﬁned based on which atypical, poten-
tially neoplastic features are present in the lesion in
question.
Adenocarcinoma
In human beings, cells with aberrant, invasive, and
metastatic characteristics are deﬁned as adenocarcinoma.
The aberrant morphologies generally are deﬁned by pat-
terns in H&E staining, including the following: multilayered
cells lacking polarity, complex glandular patterns with
irregular intervening lumens (back-to-back cribriform
glands), altered and inconsistent nuclear morphology and
positioning, and irregular chromatin patterns (eg, promi-
nent nucleoli). Proliferative rates are expected to be high,
but metaplastic lineages also can show high proliferative
rates. No present studies have deﬁned speciﬁc mutations
that might deﬁne a transition to cancer in mice. To our
knowledge, there is only 1 purely genetically driven mouse
model of epithelial carcinogenesis that results in invasive
metastatic tumors that invade to the serosal surface (and do
not just form the seemingly invasive submucosal glands
discussed earlier) and then metastasize to regional lymph
nodes.52,53 In this model, large T antigen was expressed as a
transgene in parietal cell progenitors, which eventually led
to an invasive carcinoma that was always neuroendocrine in
morphology and molecular phenotype. No speciﬁc model of
intestinal type cancer in the gastric body that is driven by
a controlled genotype of mouse (as opposed to tumors
induced by mutagens) has been reported.
16 Petersen et al Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 1
Human Disease Inception
and Progression
Chronic infection with virulent Helicobacter pylori
strains causes the most gastric adenocarcinomas world-
wide.54 H pylori is a gram-negative bacteria that inhabits
more than 50% of the global population.55 Chronic H pylori
infection can trigger changes in the fundic mucosa that
correlate with increased risk for a subset of individuals to
gastric adenocarcinoma. Most pathologists recognize
chronic atrophic gastritis as the ﬁrst lesion indicating an
increased risk for progression of an H pylori infection to
gastric cancer. This lesion pairs a chronic immune
cell inﬁltrate (including resident plasma cells, establishment
of lymphoid follicles) with oxyntic atrophy (loss of parietal
cells). As mentioned earlier, oxyntic atrophy seems to
correlate invariably with induction of SPEM.2 Thus, chronic
atrophic gastritis and SPEM appear as correlated lesions.
We discuss the literature correlating animal models of
SPEM with human lesions. Work over the past several years
by our groups and others in both human beings47,56,57 and
rodents26,34,35 has established that SPEM is a common
metaplastic phenotype observed in the atrophic human and
rodent stomachs. In the setting of a chronic inﬂammatory
inﬁltrate that does not resolve in human beings, SPEM may
progress to intestinal metaplasia.2,12 Correa58 originally
described the association of intestinal metaplasia with
the development of intestinal-type gastric cancer. When
intestinal-type gastric adenocarcinoma develops, it usually
occurs in the setting of both SPEM and intestinal metaplasia
lesions.33 Thus, the presence of metaplastic cell lineages
in the stomach carries increased risk for progression to
neoplasia. The adenocarcinomas caused by H pylori in this
setting are exceedingly heterogeneous from patient to
patient, but they vary on a spectrum from neoplastic glands
with more obviously gastric differentiation to ones with
obvious intestinal differentiation.54,56 In general, these
types of gastric cancers originally were referred to as
“intestinal-type” because they arise in the background of
intestinal metaplasia.59 It is easy to assume that the cancers,
which have varying degrees of intestinal morphology, thus
arise from the intestinal metaplasia, but that may be too
simplistic an interpretation.12,32 An alternative view, for
example, is that inducing postmitotic, differentiated cells to
re-enter the cell cycle is an inherently risky process that can
induce, unmask, or generate mutations owing to massive
changes in the chromatin landscape. Thus, abundant
metaplasia simply may reﬂect a sign of abundant, risky,
reprogramming events.11,60
Murine Models of Gastric
Preneoplasia
A review of studies over the past 20 years that show
SPEM phenotypes in association with varying degrees of
gastric neoplasia is detailed later. In particular, we review
the pathologic phenotypes of metaplasia in these models
(summarized in Table 1) and how they inform our knowl-
edge of the evolution of preneoplastic lesions.
Helicobacter infection
Mice infected with Helicobacter felis recapitulate much of
the pathology associated with H pylori infection observed in
human beings, including parietal cell loss and metaplasia,
and these bacteria have been used for years speciﬁcally
in the C57BL/6 mouse strain to study metaplasia.4–6,61
Mouse-adapted clinical isolates of H pylori from infected
human beings also can be used to recapitulate the chronic
infection and metaplasia seen in patients.62 The mechanism
by which Helicobacter causes parietal cell loss is not known.
The host inﬂammatory response, however, is thought to be
critical both in human beings and in mouse models.3,36,63–65
In general, the immune response can be categorized along 2
distinct paradigms: innate and adaptive. Innate immunity
includes the epithelial cells themselves (eg, parietal cells
produce tremendous microbial killing via acid) along with
phagocytic cells such as monocytes and granulocytes, in
particular neutrophils, that are recruited rapidly to areas of
injury or infection. The slower, adaptive immune response is
associated with antibody-producing B cells, antigen-
recognizing CD4þ T-cells, and cytotoxic CD8þ T cells.
Studies in the early 1990s focused on understanding how
the immune system contributed to the development of
gastric pathology associated with Helicobacter infection. The
inﬂammatory inﬁltrate observed in H felis–infected mice is
mixed, containing populations of lymphocytes, neutrophils,
and macrophages within the metaplastic mucosa. Roth
et al66 identiﬁed that T cells were necessary for
Helicobacter-associated parietal cell loss because
T-cell–deﬁcient mice did not develop oxyntic atrophy or
metaplasia. Murine models also have aided in the further
understanding of metaplastic events occurring after parietal
cell loss. Six months after Helicobacter infection, mice
developed oxyntic atrophy and TFF2-expressing meta-
plasia.5,6 In further studies, the mucous cell lineage expan-
sion was identiﬁed as SPEM,33 derived from the
transdifferentiation of mature chief cells.7 SPEM is highly
proliferative throughout the corpus in H felis–infected
mice.5,6,37 Although the metaplasia is extensive, intestinal
metaplasia as seen in human beings is notably absent from
Helicobacter-infected mice. However, there is evidence for
intestinalization of SPEM during chronic H felis and H pylori
infection.35,37,40
Acute Drug-Induced Models of SPEM
A caveat of using Helicobacter infection to study oxyntic
atrophy and metaplasia is that alterations, especially to the
immune system, may affect the competency of Helicobacter
to induce parietal cell loss, a prerequisite for metaplasia
development. Infection models also induce large-scale
metaplasia slowly (after approximately 6 months) and
asynchronously. Acute drug treatments that induce parie-
tal cell death directly have some advantages in that they
rapidly and synchronously induce metaplasia, bypassing
chronic immune mechanisms usually required for parietal
cell loss. This rapid and direct induction of SPEM allows
study of speciﬁc stages of metaplasia using both molecular
and histologic techniques.
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Oral administration of DMP-777. Treatment with the
parietal cell–speciﬁc protonophore drug DMP-777 leads to
rapid loss of parietal cells within 3 days, followed by in-
duction of SPEM after 10–14 days of treatment.10,34 Loss of
parietal cells is abrogated when animals are pretreated with
omeprazole before DMP-777 administration.67 Although no
proliferative chief cells were identiﬁed in the normal mu-
cosa, scattered proliferative SPEM cells were identiﬁed after
DMP-777 treatment. All of the metaplasia is reversible
within 7–14 days after cessation of DMP-777 treatment.
Interestingly, in both mice and rats, administration of DMP-
777 for up to 2 years led to prominent continuous meta-
plasia, but never resulted in any dysplastic or neoplastic
lesions.34 The absence of dysplastic lesions in the face of
chronic metaplasia appears to be caused by a lack of
inﬂammation, likely because of the other action of DMP-777
as a cell-permeant elastase inhibitor that could serve to
block neutrophil function and innate immunity.10,34,37
Intraperitoneal injections of high doses of
tamoxifen. Mice given 3 consecutive daily doses of 5 mg of
fully emulsiﬁed bolus doses of tamoxifen68 had a 90%
reduction in parietal cell mass in the stomach by 3 days
after the ﬁrst injection.26,69 High-dose tamoxifen-treated
mice also developed SPEM within 3 days of treatment with
scattered proliferative SPEM cells identiﬁed. The effect
could be reversed 2–3 weeks after drug withdrawal. The
pattern of SPEM induction by high-dose tamoxifen re-
sembles that induced by DMP-777 and also is ameliorated
by omeprazole. However, there is evidence that tamoxifen
causes more inﬂammation than DMP-777.
Oral administration of L635. L635 is a chiral molecular
cousin of DMP-777, which retains parietal cell protonophore
activity, but lacks the neutrophil elastase inhibitory capac-
ity.34 L635 treatment causes rapid induction of parietal cell
loss and SPEM in the presence of a prominent inﬂammatory
milieu. The rapid induction of oxyntic atrophy combined
with a strong inﬂammatory inﬁltrate in the gastric mucosa
leads to accelerated development of a highly proliferative
and intestinalized SPEM lineage within 3 days of treatment7
that is remarkably similar to SPEM observed after infection
with H felis.37 M2 macrophages drive the proliferation and
intestinalization of SPEM in L635-treated mice.70 Therefore,
L635 treatment provides a rapid model for the development
of highly proliferative intestinalizing SPEM.
Table 1.Pathological Lesions in Mouse Models of Metaplasia
Mouse model SPEM IM
Foveolar
hyperplasia
Proliferative
SPEM/intestinalized
SPEM
Inﬂammatory
inﬁltrate
Invasive
glands
Helicobacter species infection Yes No No Yes Yes Yes
DMP-777 treatment Yes No Yes No No No
Tamoxifen treatment Yes No Yes No Yes? No
L635 treatment Yes No Yes Yes Yes, M2
macrophage
No
Insulin-gastrin mouse Yes No Yes Yes Yes Yes
Gastrin KO mouse Accelerated
after DMP777
No No No No No
Claudin 18 KO mouse Yes No No Yes Yes, neutrophils No
KLF4 KO mouse Yes No Yes No No No
Runx3 KO Yes No No Yes No No
H/K-cholera toxin mouse Yes No Yes ND Yes, lymphocyte
follicles
No
Mist1-Kras mouse Yes Yes Yes Yes Yes, M2
macrophage
No
Smad3 KO mouse Yes,
proximal corpus
No No Yes No Yes
H/K-noggin mouse Yes No Yes No No No
Amphiregulin KO mouse Yes Yes, focal Yes Yes Yes Yes
H/K-IFNg mouse Yes No Yes Yes Yes No
HIP1r KO mouse Yes No Yes No Yes No
TxA23 mouse Yes No Yes Yes Yes No
H/K-IL1b mouse Yes No No Yes Yes Yes
K19-C2mE mouse Yes No Yes No Yes, macrophage No
GAN mouse Yes No Yes Yes Yes Yes
IL11 treatment Yes No Yes No Yes, PMN No
IL33 treatment Yes No No No Yes No
KLF4, Kruppel-like factor 4; KO, knockout; ND, not determined; PMN, polymorphonuclear leukocyte.
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Gastrin-Related Genetic Models
Located in the antrum, G cells produce gastrin to both
regulate gland homeostasis and promote acid secretion
from parietal cells, primarily through the stimulation
of histamine release from enterochromafﬁn-like cells.71,72
Gastrin also functions as a growth factor for pit cells and
exerts anti-apoptotic activity at the transcriptional
level.73–75 In the stomach, endogenous gastrin levels in-
crease in response to parietal cell loss and increase
epithelial cell proliferation and foveolar hyperplasia.76
Insulin-gastrin transgenic mice. The insulin-gastrin
mouse model uses the mouse insulin promoter to drive
expression of a human gastrin transgene, producing mod-
erate increases in circulating gastrin levels. The insulin-
gastrin mice on the FVB background develop SPEM and
then submucosal lesions in the gastric corpus that express
TFF2 by 20 months of age.4 Metaplastic changes are accel-
erated in the setting of Helicobacter infection.4 Although the
cause of parietal cell loss is unclear, a chronic state of acid
hypersecretion may contribute to the oxyntic atrophy.
Gastrin null mice. Gastrin null mice develop antral tu-
mors by 12 months of age.77,78 In the corpus, the mucosa
generally is thinner, with fewer parietal cells present. DMP-
777 treatment in gastrin null mice causes an accelerated
induction of SPEM in 1–3 days, as compared with 10 days
in wild-type mice.10,25 However, gastrin null mice do not
develop foveolar hyperplasia, which typically occurs as a
result of oxyntic atrophy, consistent with the concept that
gastrin is a major driver of foveolar hyperplasia.
Genetic Mouse Models of Parietal Cell loss
Several mouse models induce changes spontaneously,
consistent with the development of SPEM in the corpus of
the stomach. These models may initiate with a normal
mucosa and then develop increasing levels of atrophy and
metaplasia.
Claudin 18 null mice. Claudin 18 levels are high in the
normal stomach, but prominently are reduced in the meta-
plastic stomach.79 Hayashi et al79 examined the impact of
claudin-18 loss in the stomachs of claudin 18 null mice.
These mice showed few parietal cells at birth and never
developed a normal complement of parietal cells during the
postnatal period. Instead, claudin 18 null mice showed
proliferative SPEM that was associated with a signiﬁcant
neutrophil inﬁltrate and increases in IL1b expression. The
claudin 18 null stomachs also showed high levels of the
SPEM marker HE-4 (WFDC2). Although the metaplastic
SPEM lineages in the claudin 18 null mice were highly
proliferative, these mice were studied only up to 16 weeks
of age, at which time no invasive or dysplastic lesions were
reported. Thus, claudin 18 is necessary for normal parietal
cell development and gland homeostasis.
Kruppel-like factor 4 null mice. Kruppel-like factor 4 is
down-regulated in gastric cancers, and loss of Kruppel-like
factor 4 is associated with poor prognosis.80,81 In the
Kruppel-like factor 4 null mouse, the stomach shows
marked oxyntic atrophy from birth and both foveolar hy-
perplasia and mucous cell metaplasia.82 Some intrinsic
factor–expressing cells remain at the bases of corpus glands
that are dominated by a TFF2-expressing mucous cell line-
age. Although no dual labeling for intrinsic factor and TFF2
was performed, the staining for TFF2 appeared at the base
of the glands, consistent with the suggestion that these
glands represented SPEM. Interestingly, however, the in-
vestigators noted that there was little proliferation among
the SPEM lineages and even at up to a year of age, no in-
testinal metaplasia, dysplasia, or invasive lesions developed.
They also noted no inﬂammation. Thus, this model re-
sembles the stable benign metaplasia after long-term
administration of DMP-777.34
Runx3 null mice. Runx3 is a transcription factor that is
highly expressed in chief cells with lower levels of expres-
sion in surface cells and mucous neck cells.83 RUNX3 is a
gastric tumor suppressor in human beings.84 Runx3 null
mice develop marked TFF2-expressing SPEM lineages in the
corpus.85 Interestingly, Runx3 null mice do maintain pari-
etal cells, although they appear small and acid secretion is
variable. Proliferative cells are observed throughout SPEM.
In some mice, intestinalized SPEM can be observed with
expression of Muc2 and Cdx2 in deep gland regions, but no
goblet cells appear to be present. These ﬁndings are
consistent with an association of Runx3 loss with intestin-
alization.85,86 Although Runx3 null mice do not develop any
evidence of dysplasia or penetrating glands, they do show
increased susceptibility to N-Methyl-N-Nitrosourea (MNU)-
induced dysplasia in the corpus. Thus, this model suggests
that regulation of intestinalization focused in chief cell lin-
eages may promote metaplastic progression without com-
plete parietal cell loss. The phenotype of this model also
may show aspects of mucous neck cell hyperplasia accen-
tuated by the small size of remaining parietal cells.
H/K-cholera toxin mouse. Increased cyclic adenosine
monophosphate is the principal driver of parietal cell acid
secretion mediated through activation of the H2-histamine
receptor.87 Lopez-Diaz et al88 examined a model of chronic
acid overproduction in the H/K-cholera toxin mouse. This
mouse showed increased acid secretion from an early age,
as would be expected for parietal cells with increased
expression of cholera toxin and increased cyclic adenosine
monophosphate production. Although the mice showed a
normal compendium of cell lineages in the gastric corpus at
2 months of age, by 7 months of age the mice developed
increasing levels of parietal cell loss until loss was severe by
15–16 months of age. The parietal cell loss at the later time
points was associated with the presence of SPEM. The loss
of parietal cells appears to relate to the development of
autoantibodies against parietal cell antigens, especially
H/K-ATPase. This model therefore mimics the pathogenesis
of autoimmune gastritis. No invasive glands were noted in
these mice at the later stages, although measures of
proliferation were not determined.
Models of Signaling Pathway Activation
Several studies conducted on characterizing gene and
protein expression of metaplasia in the murine and human
stomachs have yet to identify a dominant signaling pathway
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driving neoplasia.25,37,89 However, different signaling
pathway aberrations in gastric cancer have been charac-
terized, identifying KRAS, ﬁbroblast growth factor receptor
2, epidermal growth factor receptor (EGFR), ERBB2, and
MET using single-nucleotide polymorphism arrays.90 These
and other signaling pathways have been investigated for
their role in the development of metaplasia.
Mitogen-activated protein kinase/ERK. Up-regulation
of phospho-ERK in metaplasia has been noted in both hu-
man beings and mice.43,91 However, Ras mutations have
been observed in only approximately 9% of gastric cancers.
Nevertheless, recent gene-proﬁling studies have noted a
signature for up-regulation of Kras activity in more than
40% of intestinal-type human gastric cancers.92,93 Choi
et al43 recently examined the induction of metaplasia in
Mist1CreERT2;LSL-KRas(G12D) mice (Mist1-Kras mice). After
tamoxifen induction, these mice expressed activated Kras in
gastric chief cells, and after 4 weeks developed proliferative
metaplasia. Three months after induction, intestinal goblet
cells expressing MUC2 were evident, progressing to invasive
glands 4 months after induction. Importantly, treatment of
the mice with a MEK inhibitor, selumetinib, caused arrest of
the metaplasia and allowed recrudescence of normal gastric
lineages. These normal lineages were derived from normal
progenitor cells and not the metaplastic lineages. The
normal gastric lineages appeared to cause extrusion of the
metaplastic glands from the gastric mucosa into the lumen.
These ﬁndings indicate that activation of Ras is involved at
all of the key steps in the development of metaplasia, from
transdifferentiation of chief cells into SPEM, to further dif-
ferentiation of intestinal metaplasia and the promotion of
invasive changes.
Hayakawa et al94 have suggested that Mist1CreERT2;LSL-
KRas(G12D) mice develop metaplasia from scattered isthmal
Mist1-expressing cells. This interpretation is at odds with
previous studies in K19-KRas(G12D)-expressing mice that
showed a phenotype dominated by foveolar hyperplasia.95
Matsuo et al96 recently conﬁrmed this phenotype of
induced foveolar hyperplasia after targeting of KRas
expression to the isthmal progenitor cells using the Runx1
eR1 promoter. In that investigation, occasional chief cells
also were targeted by eR1, and active KRas in those cells
appeared to give rise to SPEM. Thus, the majority of evi-
dence suggests that Ras activation in chief cells leads to the
development of SPEM.
TGFb and Bone Morphogenic Proteins. SMAD3 is a
critical signaling protein downstream of TGFb-receptor acti-
vation. Smad3 null mice were ﬁrst characterized extensively
for the spontaneous development of colonic adenocarci-
noma.97 Although development of colon cancers required
colonization of animals with Helicobacter hepaticus, obser-
vations at the Jackson Laboratories (Bar Harbor, ME) indi-
cated that gastric tumors evolved in the absence of any
infection. Detailed analysis of these mice subsequently
showed that Smad3 null mice developed SPEM by 6 months
of age and invasive lesions in the proximal corpus by 10
months of age.98 Invasive lesions, thought to be derived from
the ﬁrst gland of the corpus, generally showed TFF2-positive
cells along with large numbers of DCLK1-positive tuft cells.
These results suggested that loss of SMAD3 can lead to the
development of proximal gastric neoplasia.
H/K-noggin mouse. Shinohara et al99 sought to evaluate
the role of BMP signaling in the differentiation of gastric
lineages in the H/K-noggin mouse. Inhibition of BMP
signaling through overexpression of Noggin resulted in a
reduction of parietal cell numbers and expansion of SPEM
lineages expressing TFF2. Although there was increased
proliferation in the mucosa, most of this proliferation was
abolished when the transgenic mice were crossed onto a
gastrin null background, a ﬁnding consistent with a role for
proliferation in foveolar hyperplasia in these mice rather
than SPEM.75 Importantly, the overexpression of Noggin in
the stomach caused an augmentation of metaplastic changes
after infection with H felis or H pylori.100 These ﬁndings
suggest that BMP signaling generally is anti-inﬂammatory
and that loss of this signaling may promote metaplasia
development.
EGFR and EGFR ligands. The role of EGFR and its ligands
in alterations in gastric mucosal lineage differentiation has
been well established. Overexpression of TGFa in the gastric
corpus is associated with severe foveolar hyperplasia in
Ménétrier disease in human beings.17,101 Overexpression of
TGFa in the stomachs ofMetalothionein (MT)-TGFamice leads
to a similar phenotype.102,103 These studies all suggested that
overexpression of TGFa altered the differentiation of gastric
progenitors to the production of surface mucous cells over
gland cells (ie, parietal, mucous neck, and chief cells).
Nevertheless, other studies have suggested that alter-
ations in EGFR activation can inﬂuence the induction of
metaplasia. Waved-2 mice, which have an attenuating mu-
tation of the EGFR, showed enhanced development of SPEM
after loss of parietal cells induced by DMP-777.104 These
effects seemed to be speciﬁc to particular EGFR ligands
because although TGFa null mice showed no alteration in
SPEM induction, amphiregulin null mice showed an
enhanced induction of SPEM after DMP-777 treatment,
similar to that observed in waved-2 mice.105 Just as inter-
estingly, amphiregulin-deﬁcient mice older than 1 year of
age developed SPEM spontaneously.42 By 18 months of age,
more than 40% of amphiregulin null mice showed parietal
cell loss and both SPEM as well as goblet cell intestinal
metaplasia. The goblet cell intestinal metaplasia evolved in
glands also containing SPEM, and cells with intermediate
morphology with dual expression of TFF2 and MUC2 were
observed at the interface between SPEM and intestinal
metaplasia lineages.42 These ﬁndings showed that EGFR-
mediated signaling was involved in the evolution of
metaplastic lineages.
Immune-Mediated Preneoplastic Mouse Models
Inﬂammation accompanies most models of metaplasia in
the gastric mucosa. Insights into different aspects of the
inﬂammatory response show the impact of immune cells in
the progression of metaplasia.
H/K-ATPase-interferon-g transgenic mice. The
expression of the proinﬂammatory cytokine interferon
(IFN)g, typically expressed by T-helper (Th)1-polarized
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T cells, is increased in Helicobacter-infected mice. Trans-
genic overexpression of IFNg using elements of the parietal
cell–speciﬁc driver H/K-ATPase b (Atp4b) promoter caused
a prominent inﬂammatory inﬁltrate, oxyntic atrophy,
epithelial cell proliferation, and SPEM after 3.5 months.
SPEM and immune inﬁltration still were present in trans-
genic (Tg)-IFNg mice crossed to Rag1-/- mice that lacked
mature T and B cells.106 Therefore, IFNg alone can drive
metaplastic changes in the corpus without the assistance of
T or B cells.
Huntington interacting protein 1 related and Inter-
feron gamma double-knockout mice. Huntington
interacting protein 1 (Hip1) is required for normal parietal
cell maturation.107 Parietal cells undergo apoptosis in Hip1-
related (Hip1r-/-) mice and develop a robust inﬂammatory
response and SPEM by 12 months of age. Double-knockout
mice, null for both Hip1r and Ifng, have delayed metaplasia
development, but mice at 12 months of age appear to have
similar phenotypic SPEM as control Hip1R null mice.
Therefore, IFNg is not required for SPEM induction after
parietal cell loss.23
TxA23 mice. Human autoimmune gastritis occurs when
T cells target parietal cells for apoptosis in the stomach,
causing robust metaplasia that predisposes affected in-
dividuals to endocrine carcinoids.108 Transgenic BALB/c
mice engineered with CD4þ T cells that recognize the
parietal-speciﬁc antigen H/K-ATPase develop SPEM by 2–4
months of age. By 12 months of age, TxA23 mice have
extensive inﬂammation with areas of aberrant gland
morphology and penetrating submucosal glands.109 The
phenotype observed in this model may differ from most
other models of metaplasia because these mice are on a
BALB/c background.110,111 Speciﬁcally, T cells in BALB/c
mice express higher levels of IL4 than IFNg, thereby driving
a Th2-predominant response. Most investigations in the
stomach use C57BL/6 mice, which tend toward a Th1 pre-
dominant response wherein T cells express higher levels of
IFNg. Therefore, the type of metaplasia in the TxA23 atro-
phic gastritis model perhaps is indicative of a Th2-driven
environment paired with parietal cell loss.
H/K-ATPase-IL1b transgenic mice. Polymorphisms in
the Il1b gene are observed in a variety of human, including
gastric, adenocarcinomas. IL1b is part of the IL1 family of
cytokines that function as alarmins by promoting the in-
ﬂammatory response. IL1b expression increases in Heli-
cobacter infections and also is associated with myeloid cell
inﬁltration. Transgenic mice expressing human IL1b using
the H/K-ATPase promoter develop spontaneous inﬂamma-
tion, oxyntic atrophy, and SPEM with invasive lesions at late
time points. Helicobacter increases the susceptibility and
speed at which gastric pathology develops in H/K-Il1b
mice.112 Conversely, IL1-receptor antagonist treatment can
inhibit the progression of metaplasia and inﬂammatory cell
inﬁltration. Together, these ﬁndings support IL1b as a major
driver of inﬂammatory cell recruitment that promotes the
progression of metaplasia.
Stromal-derived factor 1 transgenic mice. Stromal-
derived factor 1 (SDF1) typically is expressed by cancer-
associated ﬁbroblasts and is found to be up-regulated in
Helicobacter-infected gastric mucosa. Transgenic mice
expressing SDF1 using the H/K-ATPase promoter do not
show recruitment of inﬂammatory cells, but show hyper-
proliferative gastric epithelial cells and focal areas of
SPEM with dilated glands at late time points (18 months).
H felis–infected SDF1-Tg mice develop accelerated pathol-
ogy. Similarly, when Tg-SDF1 mice are crossed to proin-
ﬂammatory Tg-IL1b mice there is increased epithelial cell
proliferation and accelerated SPEM development in the
corpus.113 These data indicate that although SDF1 does not
drive recruitment of inﬂammatory cells, it does appear to
promote epithelial changes and promote SPEM, especially in
the setting of atrophic gastritis.
K19-C2mE. Cyclooxygenase 2 (PTGS2) frequently is
overexpressed in gastric cancer. Oshima et al114 developed
transgenic mice expressing Ptgs2 and mPGES-1 in progeni-
tor cells, driven by elements from the cytokeratin 19 pro-
moter. The resulting mice showed recruitment of M2
polarized macrophages into the mucosa, subsequently
causing the development of SPEM. After 80 weeks, these
mice progress to develop hyperplastic tumors. Treatment
using the nonsteroidal anti-inﬂammatory drug meloxicam
ameliorated the inﬂammation and reversed the metaplastic
gland morphology. In an effort to determine the role of
speciﬁc cytokines in this process, Tnfa and Il1r1-/- mice
were crossed to K19-C2mE. Mice null for Tnfa had
decreased inﬂammation, reducing metaplasia overall. How-
ever, no overt change in inﬂammation or metaplasia was
observed in l1r1-/- mice. Therefore, cyclooxygenase 2 and
prostaglandin E2 can drive metaplastic changes in the
stomach through the recruitment of M2-polarized
macrophages in a TNFa-dependent pathway.114
Gan mouse. Activated b-catenin activity, but not muta-
tions in APC, is observed in 51% of human intestinal-type
gastric cancers.115 K19-promoter–expressing cells driving
Wnt1 expression caused suppression of normal gastric
epithelial cell differentiation that was accompanied with
increased proliferation and TFF2-positive cells. By 7 to 18
weeks, mice developed small preneoplastic lesions in the
corpus. The Gan mice were developed by crossing
K19-Wnt1 mice to K19-C2mE mice (described earlier),
thereby activating Wnt signaling in progenitor cells with a
coordinated immune cell inﬁltration. This results in highly
proliferative SPEM that drives the rapid development of
tumors in the corpus.116 Furthermore, amelioration of the
inﬂammatory response using a CCL2 chemokine inhibitor or
clodronate treatment to deplete macrophages causes tumor
regression in Gan mice.117 Thus, activation of the Wnt
signaling pathway can drive metaplasia formation, however,
inﬂammation is necessary for metaplasia progression.
Exogenous IL11 treatment. IL11 belongs to the IL6
family of cytokines that induces signal transduction through
the IL11RA. IL11 is not expressed during the early stages of
an inﬂammatory response associated with Helicobacter
infection, but gradually increases during chronic inﬂam-
mation and intestinal metaplasia.118 IL11 expression nor-
mally is localized to parietal cells, therefore its expression in
the stomach is lost when parietal cells die (eg, in the setting
of oxyntic atrophy in response to Helicobacter infection).
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Therefore, the source of increased IL11 expression in
chronic Helicobacter infection originates elsewhere. Never-
theless, exogenous treatment of IL11 in wild-type mice leads
to parietal cell loss within 24 hours, an inﬁltration of
polymorphonuclear cells, and the emergence of SPEM.65
Thus, it is hypothesized that IL11 is released by dying pa-
rietal cells to recruit inﬂammatory cells into the stomach
and promote the development of SPEM.
Exogenous IL33 treatment. A member of the IL1 family
of cytokines, IL33 is expressed normally in the gastric mu-
cosa, localizing to cells in the surface cell zone. IL33 syn-
ergizes to promote a Th2 inﬂammatory response that
activates innate and adaptive immune cells. IL33 generally
is classiﬁed as an alarmin because of its release into the
extracellular environment by necrotic or apoptotic cells.64
IL33-treated mice develop SPEM and a robust inﬂamma-
tory response in the lungs, intestine, and stomach, indicating
that IL33 is sufﬁcient to recruit inﬂammatory cells and drive
mucous production within respiratory and gut epithelial
tissue.64,119 However, IL33 is expressed only in the normal
stomach by cells in the surface cell (upper pit/foveolar)
zone in the corpus, and those cells are not thought to un-
dergo cell death during Helicobacter infection. Therefore,
although administration of IL33 is capable of recruiting in-
ﬂammatory cells and inducing SPEM, it remains to be seen if
endogenous IL33 functions in this capacity.
Conclusions
Data from mouse models indicate that the induction of
metaplasia involves at least 2 phases. Induction of meta-
plasia ﬁrst requires the loss of parietal cells. Parietal cell
loss induced by Helicobacter infection requires the action
of speciﬁc lymphocytic populations and speciﬁc immune
modulatory molecules. In a second phase, after, or
concomitant to, the loss of parietal cells, SPEM develops, at
least in part, from transdifferentiation of chief cells. The
expansion and maintenance of the metaplasia requires the
chronic inﬂuence of M2-macrophage subclasses. The uti-
lization of a number of drug-induced methods to ablate
parietal cells acutely can bypass the initial inﬂammatory
phase required for parietal cell loss. Similarly, genetic
models, such as directed activation of Ras in chief cells, can
bypass parietal cell loss to induce metaplasia via trans-
differentiation. Constitutive activated Ras in these meta-
plastic cells seems to be sufﬁcient to maintain and expand
metaplasia, although Ras activation also may recruit
macrophages to support the progression of metaplasia.
Mouse models of immune modulator overexpression
similarly can induce both parietal cell loss and SPEM in-
duction. It seems evident that inﬂammatory mediators are
required for induction of more aggressive and proliferative
metaplasia.
What remains unclear from mouse models is the explicit
connection between the metaplastic/atrophic lesions and
progression of carcinogenesis. Thus far, none of the models
of metaplasia progress to true metastatic, or even regionally
invasive, adenocarcinoma. In our experience, even the
mouse models termed dysplastic seem predominantly to be
exuberantly proliferative metaplastic or reactive lesions.
With the exception of the Mist1-Kras mouse and some aged
mice on the amphiregulin null background, mouse models of
metaplasia also have not faithfully recapitulated the induc-
tion of goblet cell–containing intestinal metaplasia. This
could suggest that extensive intestinal metaplasia as seen in
human beings is central to the development of adenocarci-
noma. Alternatively, intestinal metaplasia in human beings
may represent an adaptive response, occurring over years of
chronic injury rather than a true preneoplastic lesion.
Further studies are needed to discern the molecular medi-
ators of key transition points along the metaplasia-to-
carcinoma sequence: at the point of transdifferentiation of
chief cells into SPEM, at the transition of SPEM into intes-
tinal metaplasia, and at the point of true dysplastic transi-
tion from within the metaplastic milieu (SPEM or intestinal
metaplasia). Moreover, the search will continue for further
mouse models that can extend investigations to true models
of gastric adenocarcinoma development.
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